Apellis Pharmaceuticals

Filed a patent for "treatment of geographic atrophy" on Fri, March 8, 2024

Filed a patent for "dosing regimens and related compositions and methods" on Thu, August 29, 2024

Filed a patent for "dosing regimens" on Thu, August 29, 2024

Filed a patent for "treatment of complement-mediated disorders" on Tue, November 21, 2023

Filed a patent for "rnas for complement inhibition" on Thu, September 28, 2023

Filed a patent for "dosing regimens and related compositions and methods" on Thu, April 11, 2024

Filed a patent for "methods of treating eye disorders" on Thu, November 30, 2023

Filed a patent for "cell-reactive, long-acting, or targeted compstatin analogs and uses thereof" on Thu, March 7, 2024

Filed a patent for "genomic editing of complement" on Thu, April 4, 2024

Filed a patent for "genomic editing of complement" on Wed, November 22, 2023

Filed a patent for "treatment of geographic atrophy" on Fri, September 30, 2022

Filed a patent for "combination therapy for c3 inhibition" on Thu, January 12, 2023

Filed a patent for "treatment of geographic atrophy" on Mon, May 2, 2022

Filed a patent for "treatment of geographic atrophy" on Thu, June 9, 2022

Filed a patent for "cell-penetrating compstatin analogs and uses thereof" on Thu, March 9, 2023

Filed a patent for "treatment of geographic atrophy" on Thu, July 14, 2022

Filed a patent for "rnas for complement inhibition" on Thu, March 30, 2023

Filed a patent for "treatment of geographic atrophy" on Wed, August 24, 2022